BromantanevsReishi

Bromantane upregulates tyrosine hydroxylase (TH)—the rate-limiting enzyme in catecholamine synthesis—and aromatic L-amino acid decarboxylase (AADC), the enzymes responsible for converting L-tyrosine to L-DOPA and then to dopamine. This increases neuronal dopamine production capacity rather than depleting vesicular stores like traditional stimulants. The mechanism may involve modulation of transcription factors or enzyme phosphorylation. Bromantane also has anxiolytic properties through enhancement of GABAergic transmission, possibly via GABA-A receptor modulation or increased GABA synthesis. The combination of upregulated dopamine synthesis in mesolimbic and nigrostriatal pathways with GABAergic dampening of anxiety circuits produces sustained motivation, focus, and reduced mental fatigue without the jitteriness or crash typical of dopamine-releasing agents.

Reishi's triterpenes (ganoderic acids A, C, D, H; ganoderenic acids) modulate the HPA axis by reducing CRH and ACTH release, lowering cortisol via glucocorticoid receptor feedback. Ganoderic acids have direct sedative effects through GABA-A receptor modulation (possibly allosteric at the benzodiazepine site) and 5-HT2A/2C serotonergic modulation. Beta-(1,3)-(1,6)-glucan polysaccharides bind Dectin-1 and complement receptor 3 (CR3) on macrophages, natural killer cells, and dendritic cells, activating NF-kB and MAPK signaling for immune modulation. Reishi inhibits histamine release from mast cells via Fc epsilon RI downregulation and stabilizes mast cell membranes (anti-allergic effect). Antioxidant properties involve upregulation of superoxide dismutase (SOD1/SOD2), catalase, and glutathione peroxidase. Ganoderic acids may also inhibit 5-alpha-reductase and ACE.